David Sarfati-Mizrahi

Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs

Jesús Horacio Lara-Puente, Juan Manuel Carreño, Weina Sun et al. · mBio · 2021 · 52 citations · Full text

Protective Dose of a Recombinant Newcastle Disease LaSota–Avian Influenza Virus H5 Vaccine Against H5N2 Highly Pathogenic Avian Influenza Virus and Velogenic Viscerotropic Newcastle Disease Virus in Broilers with High Maternal Antibody Levels

David Sarfati-Mizrahi, Bernardo Lozano-Dubernard, Ernesto Soto-Priante et al. · Avian Diseases · 2010 · 47 citations

Vaccination, Veterinary Vaccine, Lasota Ndv Vaccine +12

Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico

Samuel Ponce‐de‐León, Martha Torres, Luis Enrique Soto-Ramírez et al. · npj Vaccines · 2023 · 39 citations · Full text

Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico

Samuel Ponce‐de‐León, Martha Torres, Luis Enrique Soto-Ramírez et al. · 2022 · 26 citations · Full text

Protection and Differentiation of Infected from Vaccinated Animals by an Inactivated Recombinant Newcastle Disease Virus/Avian Influenza H5 Vaccine

Bernardo Lozano-Dubernard, Ernesto Soto-Priante, David Sarfati-Mizrahi et al. · Avian Diseases · 2010 · 11 citations